Author Correction: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial
Hongli Gong, Shu Tian, Hao Ding, Lei Tao, Li Wang, Jie Wang, Tian Wang, Xiaohui Yuan, Yu Heng, Ming Zhang, Yong Shi, Chengzhi Xu, Chunping Wu, Shengzi Wang, Liang Zhou
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsExtracellular vesicles in disease
Correction to: Nature Communications 10.1038/s41467-024-49121-3, published online 19 June 2024
The original version of this Article contained an error in the “Secondary endpoints” section, which incorrectly read “The estimated 2-year OS, PFS, and LPR rates were 83.0% (95% CI, 67.4–91.6%), 77.1% (95% CI, 61.4–87.1%), and 70.0% (95% CI, 51.0–78.8%), 83.0% (95% CI, 67.4–91.6%)”. The correct version removes the “83.0% (95% CI, 67.4–91.6%)” at the end of this sentence. This has been corrected in both the PDF and HTML versions of the Article.